https://bbwpublisher.com/index.php/PAR/issue/feedProceedings of Anticancer Research2025-09-30T14:48:05+08:00Seven Gaoinfo@bbwpublisher.comOpen Journal Systems<p style="text-align: justify;"><em>Proceedings of Anticancer Research (PAR) </em>is an international peer-reviewed and open access journal, which is devoted to the rapid publication of high-quality original articles, reviews, case reports, short communication and letters on all aspects of experimental and clinical oncology.</p> <p style="text-align: justify;">The covered topics include, but are not limited to: cellular research and bio-markers, identification of bio-targets and agents with novel mechanisms of action, preventative and integrated treatments for cancer patients, radiation and surgery, palliative care, patient adherence, quality of life, satisfaction, and anticancer medicine, anticancer agents, novel therapies in development, cancer management, biomarkers, diagnostics, clinical trials, treatment guidelines.</p> <p align="justify"> </p>https://bbwpublisher.com/index.php/PAR/article/view/12116Zorifertinib for EGFR-mutant Non-small Cell Lung Cancer after Leptomeningeal Metastasis on Double-Dose Third-generation EGFR-TKI: A Case Report and Literature Review2025-09-30T14:48:05+08:00Ye Wangteam@bbwpublisher.comDeliang Huangteam@bbwpublisher.com<p><em>Background</em>: Leptomeningeal metastasis (LM) after third-generation EGFR-TKIs resistance carries a dismal prognosis. Limited blood–brain-barrier penetration rather than secondary EGFR mutations is the dominant resistance mechanism. We report a case managed with CNS-penetrant EGFR inhibition of zorifertinib. <em>Method</em>: A 53-year-old, never-smoking woman with EGFR L858R-mutant stage IVb non-small-cell lung cancer (NSCLC) developed LM after progression on osimertinib 160 mg and firmonertinib 160 mg. Salvage therapy with zorifertinib (200 mg BID) plus firmonertinib (80 mg qd) was initiated. <em>Results</em>: Within 14 days, the coma resolved. Karnofsky Performance Status improved from 20 to 70. Serial imaging at 3 and 5 months revealed stable disease with shrinkage according to RECIST 1.1. Only grade 1–2 diarrhea, rash, and transaminitis occurred and resolved with symptomatic care. <em>Conclusion: </em>The combination of zorifertinib plus firmonertinib provides durable intracranial control and rapid neurological recovery after third-generation EGFR-TKI failure. Prospective validation is warranted.</p>2025-09-30T14:47:49+08:00Copyright (c) 2025 Author(s)